HCC1359

HCC1359 is a human non-small cell lung carcinoma (NSCLC) cell line derived from the pleural effusion of an adult male patient. The cell line represents the large cell carcinoma subtype of NSCLC, a category characterized by large, undifferentiated malignant epithelial cells. HCC1359 cells carry a number of relevant oncogenic alterations, notably including a mutation in the *KRAS* gene, which plays a central role in driving tumorigenesis via the RAS/MAPK signaling pathway. These features make HCC1359 a useful model for studying KRAS-mutant NSCLC biology and for evaluating targeted therapies, particularly those aimed at downstream components of the KRAS signaling axis.

HCC1359 cells are adherent in culture and display morphological characteristics typical of epithelial tumor cells. The line has been utilized in various pharmacogenomic studies, particularly in high-throughput drug screening platforms that investigate genotype-specific drug sensitivities. Additionally, it has been included in several molecular profiling databases, contributing to the characterization of gene expression patterns, copy number variations, and mutation spectra in lung cancer. However, it is worth noting that the utility of HCC1359 may be limited in contexts requiring small cell lung cancer or adenocarcinoma-specific models, as it specifically reflects large cell histopathology.

37°C, 5% CO₂, humidified atmosphere.

At Cytion, we stand behind the quality and viability of our products. We guarantee that our cells will be viable at the start of culture for 60 days after shipment from our facilities. We assure that all materials conform to the specifications described in the Certificate of Analysis and/or Product Sheet.

For full details, please refer to our Warranty Statement.